|
|
此文章由 oed 原创或转贴，不代表本站立场和观点，版权归 oursteps.com.au 和作者 oed 所有！转贴必须注明作者、出处和本声明，并保持内容完整
RAP
• ResApp Health and Pfizer have agreed to increase the scheme consideration from
A$0.115 per share in cash to:
- A$0.207 per share in cash, upon satisfaction of a Confirmatory Data Readout
Condition (Confirmed Data Consideration); or
- A$0.146 per share in cash, in the event the Confirmatory Data Readout Condition is
not satisfied (Unconfirmed Data Consideration)
• Relative to ResApp’s share price prior to announcement of the Initial Scheme, the
Revised Scheme Consideration represents a material premium of:
- 130.0% based on the Confirmed Data Consideration
- 62.2% based on the Unconfirmed Data Consideration
• Draft Independent Expert Report confirms that Revised Scheme is fair and reasonable
and in best interests of ResApp shareholders
• The ResApp Board unanimously recommends that ResApp shareholders vote in favour
of the Revised Scheme |
评分
-
查看全部评分
|
回国三年之感悟-1： 大上海 (2011-8-31) 唐韵秦风 
发表于 2022-6-14 15:03
